ImmuneOncia Therapeutics, Inc. Sustainability Profile
ImmuneOncia Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in South Korea (KR), is at the forefront of developing innovative immunotherapies for cancer treatment. Founded in 2015, the company has rapidly established itself within the biotechnology industry, focusing on the discovery and development of novel therapeutic agents that harness the body's immune system to combat malignancies. ImmuneOncia's core offerings include cutting-edge monoclonal antibodies and immune-modulating therapies, distinguished by their unique mechanisms of action and potential to improve patient outcomes. With a strong emphasis on research and development, the company has achieved significant milestones, including successful clinical trials that underscore its commitment to advancing cancer care. As a leader in the immuno-oncology sector, ImmuneOncia Therapeutics continues to make strides in transforming the landscape of cancer treatment.
DitchCarbon Score
How does ImmuneOncia Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ImmuneOncia Therapeutics, Inc.'s score of 10 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ImmuneOncia Therapeutics, Inc., headquartered in South Korea (KR), currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of Yuhan Corporation, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from ImmuneOncia Therapeutics, Inc. However, emissions data and performance metrics may be inherited from its parent company, Yuhan Corporation, which operates at a cascade level of 1. This means that any climate initiatives or emissions data relevant to ImmuneOncia may be derived from Yuhan Corporation's sustainability efforts. While specific emissions figures are not available, the company is positioned within an industry increasingly focused on reducing carbon footprints and enhancing sustainability practices. ImmuneOncia Therapeutics, Inc. may align its future climate strategies with broader industry standards and initiatives, potentially adopting targets set by its parent company or through industry collaborations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 7,492,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 15,246,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is ImmuneOncia Therapeutics, Inc.'s Industry?
How Carbon Intensive is ImmuneOncia Therapeutics, Inc.'s Location?
ImmuneOncia Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ImmuneOncia Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
